artenimol has been researched along with Carcinoma, Lewis Lung in 5 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 2 (40.00) | 24.3611 |
2020's | 3 (60.00) | 2.80 |
Authors | Studies |
---|---|
Chen, J; Li, Y; Liu, W; Tang, J; Wang, Y; Xiao, X; Yang, J; Yue, F; Zhang, Y | 1 |
Chen, X; Han, N; Hu, J; Li, LG; Li, QR; Li, TF; Peng, XC; Wang, MF; Xie, ZX; Xu, HZ; Xu, X; Yang, XX; Yang, ZY; Yu, TT | 1 |
Jin, Z; Li, Y; Wang, H; Wang, Y; Xiao, X; Yang, J; Yue, F; Zhang, Y; Zhou, Q; Zhou, S | 1 |
Dai, L; Lei, J; Li, C; Liu, J; Liu, K; Wang, L | 1 |
Li, A; Lou, XE; Wang, Z; Zhang, JL; Zhou, HJ | 1 |
5 other study(ies) available for artenimol and Carcinoma, Lewis Lung
Article | Year |
---|---|
Dihydroartemisinin inhibits Lewis Lung carcinoma progression by inducing macrophages M1 polarization via AKT/mTOR pathway.
Topics: Animals; Antineoplastic Agents; Artemisinins; Carcinogenesis; Carcinoma, Lewis Lung; Cell Differentiation; Cytokines; Mice; Mice, Inbred C57BL; Oncogene Protein v-akt; Signal Transduction; Th1 Cells; TOR Serine-Threonine Kinases; Tumor Cells, Cultured; Tumor-Associated Macrophages | 2022 |
Dihydroartemisinin elicits immunogenic death through ferroptosis-triggered ER stress and DNA damage for lung cancer immunotherapy.
Topics: Animals; Carcinoma, Lewis Lung; DNA Damage; Endoplasmic Reticulum Stress; Ferroptosis; Immunotherapy; Lung Neoplasms; Mice; Tumor Microenvironment | 2023 |
Integrating network pharmacology and experimental models to investigate the mechanisms of dihydroartemisinin in preventing NSCLC progression via mTOR/HIF-1α signaling.
Topics: Animals; Apoptosis; Artemisinins; Carcinoma, Lewis Lung; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Disease Progression; Drug Evaluation, Preclinical; Female; Gene Expression Regulation, Neoplastic; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Lung Neoplasms; Mice; Network Pharmacology; Protein Interaction Maps; Signal Transduction; TOR Serine-Threonine Kinases | 2021 |
Self-assembled targeted nanoparticles based on transferrin-modified eight-arm-polyethylene glycol-dihydroartemisinin conjugate.
Topics: A549 Cells; Animals; Antineoplastic Agents; Artemisinins; Carcinoma, Lewis Lung; Cell Line, Tumor; Cell Survival; Drug Delivery Systems; Female; Humans; Hydrogen-Ion Concentration; Hydrolysis; Inhibitory Concentration 50; Ligands; Mice; Nanoparticles; Neoplasm Transplantation; Particle Size; Polyethylene Glycols; Receptors, Transferrin; Solubility; Tissue Distribution; Transferrin; Xenograft Model Antitumor Assays | 2016 |
Dihydroartemisinin improves the efficiency of chemotherapeutics in lung carcinomas in vivo and inhibits murine Lewis lung carcinoma cell line growth in vitro.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Artemisinins; Carcinoma, Lewis Lung; Cell Cycle; Cell Proliferation; Cell Survival; Cisplatin; Cyclophosphamide; Drug Screening Assays, Antitumor; Female; Humans; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Neoplasm Metastasis; Neoplasms; Random Allocation; Tumor Burden; Vascular Endothelial Growth Factor Receptor-2; Xenograft Model Antitumor Assays | 2010 |